# Telix Pharmaceuticals Partners With Ekalia for U.S. Astatine-211 Isotope Supply

- URL: https://stocks.freetheai.org/news/telix-pharmaceuticals-partners-with-ekalia-for-u-s-astatine-211-isotope-supply-de8905
- Published: 2026-10-19T05:30:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [ASX:TLX](https://stocks.freetheai.org/symbols/ASX-TLX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Telix Pharmaceuticals Limited (ASX:TLX) has partnered with Ekalia to build a scalable supply of astatine-211 in the United States. Production will begin at the RLS Trevose facility to support the company's proprietary therapeutic pipeline as well as potential third-party programs.

Securing a stable domestic supply of astatine-211 addresses key manufacturing constraints for targeted alpha therapies. The radioactive isotope will primarily support the ongoing clinical development of TLX102-Tx, an early-stage treatment candidate for brain cancers including glioblastoma and leptomeningeal disease. Expanding production capabilities across the RLS footprint may also allow the company to supply external partners and generate secondary isotope revenues.

Investors will be watching for progress toward initial production milestones, regulatory clearances, and integration into upcoming clinical trials. Telix Pharmaceuticals shares were down 2.10% at 15.4 AUD following the announcement.

## Key points

- Telix Pharmaceuticals is collaborating with Ekalia to produce astatine-211 in the United States.
- Initial production will start at RLS Trevose to support clinical development of brain cancer therapy TLX102-Tx.
- The partnership aims to relieve supply bottlenecks for targeted alpha therapies and offer capacity to third parties.
- Telix Pharmaceuticals shares fell 2.10% to 15.4 AUD.

## Questions and answers

### What is Telix Pharmaceuticals doing with Ekalia?

Telix Pharmaceuticals is collaborating with Ekalia to establish scalable U.S. production of the isotope astatine-211, starting at the RLS Trevose facility.

### Which drug pipeline programs will benefit from this partnership?

The new supply of astatine-211 will support Telix's early-stage targeted alpha therapy candidate TLX102-Tx, which focuses on glioblastoma and leptomeningeal disease.

### Will Telix supply astatine-211 to third parties?

Yes, the collaboration creates capacity to supply third-party programs in addition to supporting Telix's internal drug pipeline.